Abstract
Background: Astroglioma, one major form of brain tumors, has remained principally tough to handle for decades, due to the complexity of tumor pathology and the poor response to chemo- and radio-therapies.
Methods: Our previous study demonstrated that nifurtimox could regulate the signaling axis of AKT-GSK3β in various tumor types including the astroglioma U251 cells. Intriguingly, earlier case studies suggested that nifurtimox could possibly permeate the blood brain barrier and arrest neuroblastoma in the brain. These observations jointly encouraged us to explore whether nifurtimox would hinder the growth of astroglioma in vivo.
Results: Our results exhibited that nifurtimox could competently hinder the development of astroglioma in the mouse brain as compared to temozolomide, the first line of drug for brain tumors. Meanwhile the surviving rate, as well as the body-weight was dramatically upregulated upon nifurtimox treatment, as compared to that of temozolomide. These findings offered nifurtimox as a better alternative drug in treating astroglioma in vivo.
Conclusion: Persistently, the manipulation of the signaling axis of AKT-GSK3β in astroglioma was found in line with earlier findings in neuroblastoma when treated with nifurtimox.
Keywords: Astroglioma, Nifurtimox treatment, Temozolomide, in vivo, AKT-GSK3β, blood brain barrier.
Related Books
Oxygen, the Breath of Life: Boon and Bane in Human Health, Disease, and Therapy
Evaluation of Cellular Processes by In Vitro Assays
Free Radical Biomedicine: Principles, Clinical Correlations, and Methodologies
GPI Membrane Anchors – The Much Needed link
MCQs Series for Life Sciences
MCQs Series for Life Sciences
Sialobiology: Structure, Biosynthesis and Function. Sialic Acid Glycoconjugates in Health and Disease
Synthesis and Biological Applications of Glycoconjugates
The Art and Science of Poisons
Sex Steroids and Apoptosis In Skeletal Muscle: Molecular Mechanisms
18
